May of this year, a patient with glioblastoma (GBM) was denied access to Dr.
Burzynski’s potentially life-saving antineoplaston treatment because the FDA
judged that “the potential benefits [did not] justify the potential risks of
the treatment.” GBM is a highly malignant form of brain cancer and is extremely
difficult to treat, while antineoplaston therapy is a natural
and effective treatment with a long history of safe use.
FDA did not actually challenge the fact that the antineoplaston treatment is
safe; the agency seems to believe there is no perceived benefit to the
treatment, even though the actual effectiveness of the treatment is not in
doubt. Why is the FDA denying patients access to a potentially lifesaving
treatment when nothing else works? These are exactly the kinds of situations
that compassionate use and expanded access were made for—patients with no other
options who want access to experimental treatments.
the FDA to allow antineoplaston treatment for terminal patients, both children
personalize and add your own comments if you have time!
Please Give Dying Patients Access to Antineoplaston Treatment!
Dear [Decision Maker],
Sincerely,[Your Name] [Your Address] [City, State ZIP]